Multi-Color Corporation Successfully Completes Comprehensive Financial Restructuring


Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are changes in the global, political, economic, business, competitive, market, supply chain, and regulatory forces, future exchange and interest rates, changes in tax rates and any future business combinations or dispositions, uncertainties and costs related to the RSA and the Chapter 11 process, including, among others, potential adverse effects of the Chapter 11 process on the Company’s liquidity and results of operations, including with respect to its relationships with its customers, distribution partners, suppliers, and other third parties; employee attrition and the Company’s ability to retain senior management and other key personnel due to the distractions and uncertainties inherent in the Chapter 11 process; the impact of any cost reduction initiatives; any other legal or regulatory proceedings; the Company’s ability to obtain operating capital, including complying with the restrictions imposed by the terms and conditions of any debtor-in-possession financing, such as the financing mentioned herein; and the risk that any plan of reorganization resulting therefrom may not be implemented at all. Please see the Amended Joint Prepackaged Plan of Reorganization of Multi-Color Corporation and its Debtor Affiliates Pursuant to Chapter 11 of the Bankruptcy Code [Docket No. 754] and the Disclosure Statement Relating to the Joint Prepackaged Plan of Reorganization of Multi-Color Corporation and its Debtor Affiliates Pursuant to Chapter 11 of the Bankruptcy Code [Docket No. 18], for additional considerations and risk factors associated with the company’s Chapter 11 process. Nothing in this press release is intended as a profit forecast or estimate for any period and no statement in this press release should be interpreted to mean that the financial performance for the Company for the current or future financial years would necessarily match or exceed its historical results. Further, this press release is not intended to and does not constitute and should not be construed as, considered a part of, or relied on in connection with any information or offering memorandum, security purchase agreement, or offer, invitation or recommendation to underwrite, buy, subscribe for, otherwise acquire, or sell any securities or other financial instruments or interests or any other transaction.



Source link

  • Related Posts

    Dr. Marty Makary is out as FDA commissioner

    Dr. Marty Makary is out as commissioner of the Food and Drug Administration, the fourth high-profile departure of a member of the Trump administration this year, according to two people…

    Ebay is right to flip the bird at media-hungry GameStop overlord Ryan Cohen

    Ryan Cohen (aka RC on X, per his legion of followers) suffered his latest setback on Tuesday. Online marketplace eBay (EBAY) — chaired by former Gap (GAP) CEO and Disney…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    New Brunswick’s government proposes overhaul of lobbying rules – New Brunswick

    New Brunswick’s government proposes overhaul of lobbying rules – New Brunswick

    Googlebooks: The Ultimate Laptop for Android Users? video

    Googlebooks: The Ultimate Laptop for Android Users? video

    Deal of the day: Fly nonstop to Tahiti from 25,000 Capital One miles

    Deal of the day: Fly nonstop to Tahiti from 25,000 Capital One miles

    US university’s commencement speaker reveals he will pay off students’ final-year loans | US universities

    US university’s commencement speaker reveals he will pay off students’ final-year loans | US universities

    Their son died of a drug overdose after consulting ChatGPT. Now they’re suing OpenAI.

    Their son died of a drug overdose after consulting ChatGPT. Now they’re suing OpenAI.

    Dr. Marty Makary is out as FDA commissioner

    Dr. Marty Makary is out as FDA commissioner